Whitney Blakley, MD
Obesity Medicine · Indianapolis, INNPI 1598108813
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $161,309 of the $182,044 with a category attached, or 88.6%. 11 manufacturers reported payments, led by Novo Nordisk at 59.0% of the total. 2025 is the largest year on record at $77,024, more than ten times the $263 reported in 2019.
Across 300 payments — averaging $606.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$107K
- Lilly USA, LLC$74K
- AbbVie$36
- Endo Pharmaceuticals Inc.$30
- Eagle Pharmaceuticals, Inc.$24
- Teleflex LLC$21
- plus $79 from 5 others
What the payments were for
- Consulting fees$3,3352%
- Speaking & faculty fees$161,30989%
- Travel & lodging$9,3325%
- Food & beverage$8,0684%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 154 | $107,469 |
| Lilly USA, LLC | 135 | $74,385 |
| AbbVie | 2 | $36 |
| Endo Pharmaceuticals Inc. | 2 | $30 |
| Eagle Pharmaceuticals, Inc. | 1 | $24 |
| Teleflex LLC | 1 | $21 |
| Vertex | 1 | $20 |
| Vivus LLC | 1 | $17 |
| Cook Medical LLC | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few obesity medicine providers in Indianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $78,891 |
| MounjaroTirzepatide | 36 | $57,062 |
| Topiramate | 43 | $232 |
| Metformin Hcl ErMetformin Hcl | 26 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $107,469 | $78,89146 claims |
| Lilly USA, LLCMounjaro | $74,385 | $57,06236 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obesity medicine providers in Indianaon file to place this against a meaningful peer group, so we don't.
Other obesity medicine in Indianapolis
- Cynthia GlentzerIndianapolis$1K
- Eileen ThomasonIndianapolis$566
- Michael SimpsonHobart$4K
- Mustafa NakawaMerrillville$1K
- Lisa TrittoChesterton$883
- Srinivasu KesaCarmel$531
- Mary ReillyZionsville$159
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.